Shattuck Labs, Inc. Financing Cash Flow
Shattuck Labs, Inc. (STTK) reported Financing Cash Flow of $153.81 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-11
- Shattuck Labs, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $128.01M.
- Shattuck Labs, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $25.80M.
- Shattuck Labs, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $134.00K.
- Shattuck Labs, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $44.50M, a 193365.22% increase year-over-year.
- Shattuck Labs, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $44.57M, a 5563.79% increase from fiscal 2024.
- Shattuck Labs, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $787.00K, a 98.38% decline from fiscal 2023.
- Shattuck Labs, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $48.62M, a 28330.41% increase from fiscal 2022.
- Shattuck Labs, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $171.00K, a 91.14% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $128.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $153.81M 10-Q · filed 2026-08-11 | $153.95M derived: sum of 3 quarters · filed 2026-08-11 | $198.44M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $25.80M 10-Q · filed 2026-05-07 | $25.94M derived: sum of 2 quarters · filed 2026-05-07 | $70.43M derived: sum of 3 quarters · filed 2026-05-07 | $70.43M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $134.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $44.63M derived: sum of 2 quarters · filed 2026-03-05 | $44.63M derived: sum of 3 quarters · filed 2026-08-11 | $44.57M 10-K · filed 2026-03-05 |
| 2025-09-30 | $44.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $44.50M derived: sum of 2 quarters · filed 2026-08-11 | $44.44M 10-Q · filed 2025-11-06 | $44.37M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$57.00K 10-Q · filed 2026-08-11 | -$129.00K derived: sum of 3 quarters · filed 2026-08-11 | -$106.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$57.00K 10-Q · filed 2026-05-07 | -$129.00K derived: sum of 2 quarters · filed 2026-05-07 | -$106.00K derived: sum of 3 quarters · filed 2026-05-07 | $914.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$72.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$49.00K derived: sum of 2 quarters · filed 2026-03-05 | $971.00K derived: sum of 3 quarters · filed 2026-03-05 | $787.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | $23.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.04M derived: sum of 2 quarters · filed 2025-11-06 | $859.00K 10-Q · filed 2025-11-06 | $49.42M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $1.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $836.00K 10-Q · filed 2025-08-14 | $49.40M derived: sum of 3 quarters · filed 2025-08-14 | $49.42M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$184.00K 10-Q · filed 2025-05-01 | $48.38M derived: sum of 2 quarters · filed 2025-05-01 | $48.40M derived: sum of 3 quarters · filed 2025-05-01 | $48.43M derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | $48.56M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $48.58M derived: sum of 2 quarters · filed 2025-03-27 | $48.62M derived: sum of 3 quarters · filed 2025-03-27 | $48.62M 10-K · filed 2025-03-27 |
| 2023-09-30 | $21.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $54.00K derived: sum of 2 quarters · filed 2024-11-14 | $54.00K 10-Q · filed 2024-11-14 | $54.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $33.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $33.00K 10-Q · filed 2024-08-01 | $33.00K derived: sum of 3 quarters · filed 2024-08-01 | $60.00K derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-02 | $0.00 derived: sum of 2 quarters · filed 2024-05-02 | $27.00K derived: sum of 3 quarters · filed 2024-05-02 | $37.00K derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $27.00K derived: sum of 2 quarters · filed 2024-02-29 | $37.00K derived: sum of 3 quarters · filed 2024-02-29 | $171.00K 10-K · filed 2024-02-29 |
| 2022-09-30 | $27.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $37.00K derived: sum of 2 quarters · filed 2023-11-09 | $171.00K 10-Q · filed 2023-11-09 | $461.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $144.00K 10-Q · filed 2023-08-10 | $434.00K derived: sum of 3 quarters · filed 2023-08-10 | $786.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $134.00K 10-Q · filed 2023-05-09 | $424.00K derived: sum of 2 quarters · filed 2023-05-09 | $776.00K derived: sum of 3 quarters · filed 2023-05-09 | $2.03M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $290.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $642.00K derived: sum of 2 quarters · filed 2023-02-23 | $1.90M derived: sum of 3 quarters · filed 2023-02-23 | $1.93M 10-K · filed 2023-02-23 |
| 2021-09-30 | $352.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $1.61M derived: sum of 2 quarters · filed 2022-11-09 | $1.64M 10-Q · filed 2022-11-09 | $216.47M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $1.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $1.29M 10-Q · filed 2022-08-11 | $216.12M derived: sum of 3 quarters · filed 2022-08-11 | $215.03M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $31.00K 10-Q · filed 2022-05-12 | $214.86M derived: sum of 2 quarters · filed 2022-05-12 | $213.78M derived: sum of 3 quarters · filed 2022-05-12 | $296.46M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $214.83M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $213.75M derived: sum of 2 quarters · filed 2022-03-15 | $296.43M derived: sum of 3 quarters · filed 2022-03-15 | $330.87M 10-K · filed 2022-03-15 |
| 2020-09-30 | -$1.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $81.60M derived: sum of 2 quarters · filed 2021-11-09 | $116.04M 10-Q · filed 2021-11-09 | $115.97M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $82.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $117.12M 10-Q · filed 2021-08-12 | $117.06M derived: sum of 3 quarters · filed 2021-08-12 | |
| 2020-03-31 | $34.43M 10-Q · filed 2021-05-10 | $34.37M derived: sum of 2 quarters · filed 2021-05-10 | ||
| 2019-12-31 | -$64.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | -$64.00K 10-K · filed 2021-03-16 | ||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |